Epoetin delta

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Name
Epoetin delta
Accession Number
DB11624
Type
Biotech
Groups
Approved, Investigational, Withdrawn
Biologic Classification
Protein Based Therapies
Other protein based therapies
Description

Epoetin Delta is an ingredient in the EMA-withdrawn product Dynepo.

Protein chemical formula
Not Available
Protein average weight
Not Available
Sequences
Not Available
Synonyms
Not Available
External IDs
HMR-4396 / HMR4396
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
DynepoInjection, solution3000 IUIntravenous; SubcutaneousShire Pharmaceutical Contracts Limited2002-03-182009-04-23Eu
DynepoInjection, solution2000 IUIntravenous; SubcutaneousShire Pharmaceutical Contracts Limited2002-03-182009-04-23Eu
DynepoInjection, solution5000 IUIntravenous; SubcutaneousShire Pharmaceutical Contracts Limited2002-03-182009-04-23Eu
DynepoInjection, solution8000 IUIntravenous; SubcutaneousShire Pharmaceutical Contracts Limited2002-03-182009-04-23Eu
DynepoInjection, solution1000 IUIntravenous; SubcutaneousShire Pharmaceutical Contracts Limited2002-03-182009-04-23Eu
DynepoInjection, solution10000 IUIntravenous; SubcutaneousShire Pharmaceutical Contracts Limited2002-03-182009-04-23Eu
DynepoInjection, solution6000 IUIntravenous; SubcutaneousShire Pharmaceutical Contracts Limited2002-03-182009-04-23Eu
DynepoInjection, solution4000 IUIntravenous; SubcutaneousShire Pharmaceutical Contracts Limited2002-03-182009-04-23Eu
Additional Data Available
  • Application Number
    Application Number

    A unique ID assigned by the FDA when a product is submitted for approval by the labeller.

    Learn more
  • Product Code
    Product Code

    A governmentally-recognized ID which uniquely identifies the product within its regulatory market.

    Learn more
Categories
UNII
474EI5756Y
CAS number
261356-80-3

Pharmacology

Indication
Not Available
Associated Conditions
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
CyclophosphamideThe risk or severity of pulmonary toxicity can be increased when Epoetin delta is combined with Cyclophosphamide.
VinblastineThe risk or severity of peripheral neuropathy can be increased when Epoetin delta is combined with Vinblastine.
VincamineThe risk or severity of peripheral neuropathy can be increased when Epoetin delta is combined with Vincamine.
VincristineThe risk or severity of peripheral neuropathy can be increased when Epoetin delta is combined with Vincristine.
VindesineThe risk or severity of peripheral neuropathy can be increased when Epoetin delta is combined with Vindesine.
VinflunineThe risk or severity of peripheral neuropathy can be increased when Epoetin delta is combined with Vinflunine.
VinorelbineThe risk or severity of peripheral neuropathy can be increased when Epoetin delta is combined with Vinorelbine.
VintafolideThe risk or severity of peripheral neuropathy can be increased when Epoetin delta is combined with Vintafolide.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

References

General References
Not Available
External Links
Not Available

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3TerminatedTreatmentAnemias / Renal Failure1
4TerminatedNot AvailableAnemias / Chronic Renal Failure (CRF)1
Not AvailableTerminatedNot AvailableAnemias / Chronic Renal Failure (CRF) / Kidney Diseases1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
Injection, solutionIntravenous; Subcutaneous1000 IU
Injection, solutionIntravenous; Subcutaneous10000 IU
Injection, solutionIntravenous; Subcutaneous2000 IU
Injection, solutionIntravenous; Subcutaneous3000 IU
Injection, solutionIntravenous; Subcutaneous4000 IU
Injection, solutionIntravenous; Subcutaneous5000 IU
Injection, solutionIntravenous; Subcutaneous6000 IU
Injection, solutionIntravenous; Subcutaneous8000 IU
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Taxonomy

Description
Not Available
Kingdom
Organic Compounds
Super Class
Organic Acids
Class
Carboxylic Acids and Derivatives
Sub Class
Amino Acids, Peptides, and Analogues
Direct Parent
Peptides
Alternative Parents
Not Available
Substituents
Not Available
Molecular Framework
Not Available
External Descriptors
Not Available

Drug created on October 17, 2016 14:07 / Updated on June 04, 2019 07:24